Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arte
Hexanoyl glycine is an acylated amino acid that is used as a urinary biomarker for several indications. It is normally biosynthesized from hexanoyl-CoA and glycine by the mitochondrial enzyme glycine N-acyltransferase. Increased urinary excretion of hexanoyl glycine in humans is indicative of a deficiency in medium-chain acyl-CoA dehydrogenase. Increased urinary hexanoyl glycine can also be used as a biomarker for exposure to gamma radiation. Levels of hexanyl glycine can also be elevated during cancer, while they are decreased 20-fold in mice following treatment with the PPARα ligand Wy 14643.
GB1874 inhibitor of the Wnt pathway that targets the β-cat-TCF4 PPI. GB1874 also affected the proliferation and stemness of Wnt-addicted colorectal cancer (CRC) cells in vitro. Encouragingly, GB1874 inhibited the growth of CRC tumor xenografts in vivo, thus demonstrating its potential for further development into therapeutics against Wnt-associated cancer indications.
D-4418 is a PDE4 inhibitor. It has been in development as a novel anti-inflammatory therapy with asthma and chronic obstructive pulmonary disease being primary indications.
IACS-010759 is a potent inhibitor of complex I of OXPHOS with orally bioavailable. IACS-10759 effectively inhibits ATP production and oxygen consumption in isolated mitochondria, and inhibits the conversion of NADH to NAD+ in immunoprecipitated complex I
AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin i
PF-376304 is a nonspecific PI3K inhibitor under development for anti-inflammatory indications. Phosphoinositide 3-kinase (PI3K) is an enzyme fundamental to the regulation of various metabolic processes.
PF-303 is a covalent-reversible BTK inhibitor. Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for the treatment of oncologic and autoimmune indications.